מיפג'ין

Nazione: Israele

Lingua: ebraico

Fonte: Ministry of Health

Principio attivo:

MIFEPRISTONE

Commercializzato da:

A. LAPIDOT PHARMACEUTICALS, LTD

Codice ATC:

G03XB01

Forma farmaceutica:

טבליה

Composizione:

MIFEPRISTONE 200 MG

Via di somministrazione:

פומי

Tipo di ricetta:

מרשם נדרש

Prodotto da:

EXELGYNE LABORATORIES, FRANCE

Gruppo terapeutico:

MIFEPRISTONE

Area terapeutica:

MIFEPRISTONE

Indicazioni terapeutiche:

Medical alternative to uterine suction for termination of intra-utrerine Pregnancy: - up to and no later than 49 days of amenorrhea (seven weeks) - in sequential use with a prostaglandin analogue misoprostol 400 mcg per os administered 36 to 48 hours after Mifegyne intake. Under these conditions the association of mifepristone and prostaglandins leads to a success rate of about 95 per cent of the cases. Preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reason (beyond the first trimester). Softening and dilatation of the cervix uteri prior to surgical termination of pregnancy during the first trimester.

Data dell'autorizzazione:

2014-07-31